Abstract:Graphical Preclinical studies support the role of BDNF as a biomarker in Neuropathic Pain. This study identified several methodological considerations that need to be accounted for when measuring BDNF peripherally. Additional longitudinal investigations are needed to develop standardized guidelines to measure serum BDNF and to clearly determine its role in the diagnosis and treatment of neuropathic pain. Introduction The primary objective of this paper is to (1) provide a summary of human studies that have used brain derived neurotrophic factor (BDNF) as a biomarker, (2) review animal studies that help to elucidate the mechanistic involvement of BDNF in the development and maintenance of neuropathic pain (NP), and (3) provide a critique of the existing measurement techniques to highlight the limitations of the methods utilized to quantify BDNF in different biofluids in the blood (i.e., serum and plasma) with the intention of presenting a case for the most reliable and valid technique. Lastly, this review also explores potential moderators that can influence the measurement of BDNF and provides recommendations to standardize its quantification to reduce the inconsistencies across studies. Methods In this manuscript we examined the literature on BDNF, focusing on its role as a biomarker, its mechanism of action in NP, and critically analyzed its measurement in serum and plasma to identify factors that contribute to the discrepancy in results between plasma and serum BDNF values. Results A large heterogenous literature was reviewed that detailed BDNF's utility as a potential biomarker in healthy volunteers, patients with chronic pain, and patients with neuropsychiatric disorders but demonstrated inconsistent findings. The literature provides insight into the mechanism of action of BDNF at different levels of the central nervous system using animal studies. We identified multiple factors that influence the measurement of BDNF in serum and plasma and based on current evidence, we recommend assessing serum BDNF levels to quantify peripheral BDNF as they are more stable and sensitive to changes than plasma BDNF. Conclusion Although mechanistic studies clearly explain the role of BDNF, results from human studies are inconsistent. More studies are needed to evaluate the methodological challenges in using serum BDNF as a biomarker in NP.

Clinical measures in chronic neuropathic pain are related to the Kennedy and endocannabinoid pathways

The Identification of Blood Biomarkers of Chronic Neuropathic Pain by Comparative Transcriptomics

The related mechanism of complete Freund's adjuvant-induced chronic inflammation pain based on metabolomics analysis

Neurokinin-2 Receptor Levels Correlate with Intensity, Frequency, and Duration of Pain in Chronic Pancreatitis.

Alterations of endogenous pain-modulatory system of the cerebral cortex in the neuropathic pain

Association of Serum Endocannabinoid Levels with Pancreatitis and Pancreatitis-Related Pain

Transcriptomic and proteomic profiling of the anterior cingulate cortex in neuropathic pain model rats

Corticomotor excitability is altered in central neuropathic pain compared with non-neuropathic pain or pain-free patients

Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination

Corneal neuropathic pain: a review to inform clinical practice

Neuropathic corneal pain: Tear proteomic and neuromediator profiles, imaging features, and clinical manifestations

BDNF as a biomarker for neuropathic pain: Consideration of mechanisms of action and associated measurement challenges

Towards a neurobiological understanding of pain in chronic pancreatitis: mechanisms and implications for treatment

Clinical significance of methyl-CpG binding protein 2 in postherpetic neuralgia: an observational study

The Endocannabinoid System in the Brain Undergoes Long-Lasting Changes Following Neuropathic Pain

Chronic neuropathic pain reduces opioid receptor availability with associated anhedonia in rat

Endocannabinoids and related lipids linked to social exclusion in individuals with chronic non-medical prescription opioid use

Alterations in mouse spinal cord and sciatic nerve microRNAs after the chronic constriction injury (CCI) model of neuropathic pain

Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain

Identification of Differentially Expressed Genes and Key Pathways in the Dorsal Root Ganglion after Chronic Compression.

Pain, depression, and poor quality of life in chronic pancreatitis: Relationship with altered brain metabolites